Exosomal profiling should be used to monitor disease activity in MS patients: Yes DOI
Marcin P. Mycko

Multiple Sclerosis Journal, Год журнала: 2023, Номер 29(10), С. 1204 - 1205

Опубликована: Сен. 1, 2023

Язык: Английский

Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis DOI Creative Commons
B. Singer,

Dawn Morgan,

Julie A Stamm

и другие.

Neurology and Therapy, Год журнала: 2024, Номер unknown

Опубликована: Сен. 4, 2024

Язык: Английский

Процитировано

1

Cytomegalovirus immune responses are associated with lower serum NfL and disability accumulation risk at multiple sclerosis onset DOI
Jan D. Lünemann,

Augusto Sao Avilés,

Mar Tintoré

и другие.

Multiple Sclerosis Journal, Год журнала: 2024, Номер unknown

Опубликована: Сен. 9, 2024

Infection by cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) play a prognostic role in multiple sclerosis (MS).

Язык: Английский

Процитировано

1

Multi-organ imaging-derived polygenic indexes for brain and body health DOI Creative Commons
Xiaochen Yang, Patrick F. Sullivan, Bingxuan Li

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Апрель 20, 2023

The UK Biobank (UKB) imaging project is a crucial resource for biomedical research, but limited to 100,000 participants due cost and accessibility barriers. Here we used genetic data predict heritable imaging-derived phenotypes (IDPs) larger cohort. We developed evaluated 4,375 IDP scores (IGS) derived from UKB brain body images. When applied who were not imaged, IGS revealed links numerous stratified at increased risk both somatic diseases. For example, identified individuals higher Alzheimer's disease multiple sclerosis, offering additional insights beyond traditional polygenic of these independent external cohorts, also those high in the All Us Research Program Disease Neuroimaging Initiative study. Our results demonstrate that, while cohort largely healthy may be most enriched management, it holds immense potential stratifying various diseases broader cohorts.

Язык: Английский

Процитировано

2

VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis DOI Creative Commons
Shivam Patel,

Seamus Rafferty,

Laura Patricia González Aquino

и другие.

Multiple Sclerosis Journal, Год журнала: 2024, Номер 30(4-5), С. 585 - 593

Опубликована: Фев. 15, 2024

Background: Despite advancements in treatments of multiple sclerosis (MS), there is a lack awareness early MS symptoms, especially students and the public, contributing to delays diagnosis treatment. This review aims identify gaps tools increase provide bilingual framework facilitate recognition symptoms. Methods: We performed literature determine use English Spanish mnemonics education for medical patients. Results: There no educational tool help remember signs at present. Here we present encompassed VISIBLY (English) VISIBLE (Spanish). stands (1) Vision changes: Painful vision loss, loss color or double vision; (2) Belly Back numbness Balance issues; (3) Limb weakness Numbness; (4), Young people. version included manuscript. Conclusion: posit that VISIBL-MS provides addresses interconnection between language, culture, health literacy, outcomes can be useful tackle effects literacy on diverse communities.

Язык: Английский

Процитировано

0

Molekulare Biomarker bei neuroinflammatorischen Erkrankungen DOI
Louisa Müller‐Miny, Jan D. Lünemann

Fortschritte der Neurologie · Psychiatrie, Год журнала: 2024, Номер 92(11), С. 468 - 481

Опубликована: Ноя. 1, 2024

Biomarker gelten als Schlüsselelement für die Umsetzung von Präzisionsmedizin. Technische Fortschritte in der Quantifizierbarkeit ZNS-Molekülen im peripheren Blut und Design klinischen Studien zur Identifizierung Validierung Biomarkern haben den letzten Jahren zu einer starken Dynamik Biomarkerentwicklung sowohl bei entzündlichen auch degenerativen Erkrankungen des Nervensystems geführt. Die vorliegende Übersicht fasst aktuellen Stand Entwicklungslinien molekularen neurologischen zusammen.

Процитировано

0

On how SAM might help improving personalized treatments in relapsing-remitting multiple sclerosis DOI
Nguyen Quoc Khanh Le

European Radiology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 15, 2024

Язык: Английский

Процитировано

0

Emerging biomarkers for improving pregnancy planning in multiple sclerosis DOI Creative Commons
Juan Pablo Cuello,

Ariana Meldaña Rivera,

Enric Monreal

и другие.

Frontiers in Neurology, Год журнала: 2024, Номер 15

Опубликована: Фев. 15, 2024

Background Patient disability, relapse rate, and age are used for family planning in multiple sclerosis (MS). However, the need more accurate biomarkers is widely recognized. We aimed to explore influence of on neurofilament light chain (sNfL), which reflects acute inflammation; glial fibrillary acidic protein (GFAP), associated with disability progression independent relapses; anti-Müllerian hormone (AMH), reflecting ovarian reserve, provide a tailored strategy. Methods This case-control study included 95 MS patients 61 healthy control women (HCW). sNfL GFAP levels were measured using sensitive single-molecule array assay. AMH by automated Elecsys ® Anti-Müllerian Hormone Assay. Results observed no significant differences values between group within any age-matched categories. Age exhibited negative correlation both groups, as expected. Nevertheless, our findings suggest slight tendency toward reduced reserve (rho = −0.67, p < 0.0001; rho HCW −0.43, 0.0006). Interestingly, among 76 participants under 40 years old, we identified ten individuals (13.1%) below 0.7 ng/ml, indicative low an additional six (7.8%) ng/ml 0.9 suggesting potential risk premature failure. Conversely, high variability but showed association intervals. Conclusion found AMH, or The assessment sNFL at onset facilitates personalized therapeutic strategies childbearing-age women.

Язык: Английский

Процитировано

0

Novel imaging approaches in multiple sclerosis DOI
Mauricio Farez

Elsevier eBooks, Год журнала: 2024, Номер unknown, С. 35 - 86

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0

Serum glial fibrillary acidic protein as a marker of brain MRI metrics in multiple sclerosis: A scoping review DOI Creative Commons
Noah Marini,

Nikolai Lesack,

Sama Alizadeh

и другие.

Journal of Neuroimaging, Год журнала: 2024, Номер 34(5), С. 497 - 504

Опубликована: Авг. 22, 2024

Abstract Background and Purpose Magnetic resonance imaging (MRI) is heavily relied upon for the diagnosis monitoring of multiple sclerosis (MS), a chronic, demyelinating disease central nervous system. Serum biomarkers may serve as an accessible tool increasing sensitivity, improving accessibility, corroborating symptoms, providing additional data to guide clinical management. This scoping review investigates current understanding how serum biomarker glial fibrillary acidic protein (sGFAP) relates brain MRI metrics. Methods We adhered Joanna Briggs Institute methodology reviews Preferred Reporting Items Systematic Meta‐Analyses guidelines. The databases Medline (Ovid), Embase CINAHL (Ebsco), Web Science (University British Columbia institutional access) were searched on August 24, 2023 using combination medical subject headings keyword terms topic in MS. Results A total 9880 articles retrieved which 6271 unique titles abstracts screened. Twelve 259 resultant papers contained sGFAP proceeded extraction. It was found that lesion metrics generally had positive relationship with sGFAP, while gray matter white metrics, including normal‐appearing matter, related negatively or not at all. Conclusions These results highlight be specific MS, it have utility sensitivity postdiagnosis MS progression.

Язык: Английский

Процитировано

0

Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomes DOI Creative Commons

Paula Terroba-Navajas,

Marianna Spatola,

Omar Chuquisana

и другие.

Med, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Язык: Английский

Процитировано

0